Mitchell Gold - Dec 8, 2023 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC. (ALPN)

Role
Executive Chairman and CEO, Director
Signature
/s/ James Paul Rickey, attorney-in-fact
Stock symbol
ALPN
Transactions as of
Dec 8, 2023
Transactions value $
-$2,033,961
Form type
4
Date filed
12/12/2023, 09:02 PM
Previous filing
Jan 5, 2023
Next filing
Dec 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALPN Common Stock Sale -$138K -8.07K -7.37% $17.08 101K Dec 8, 2023 Direct F1, F2
transaction ALPN Common Stock Sale -$1.19M -68.9K -67.97% $17.26 32.5K Dec 11, 2023 Direct F1, F3
transaction ALPN Common Stock Sale -$562K -32.5K -100% $17.32 0 Dec 12, 2023 Direct F1, F4
transaction ALPN Common Stock Options Exercise $3.88K +8.61K $0.45* 8.61K Dec 12, 2023 Direct F1
transaction ALPN Common Stock Sale -$149K -8.61K -100% $17.32 0 Dec 12, 2023 Direct F1, F4
holding ALPN Common Stock 2.6M Dec 8, 2023 Alpine ImmunoSciences, L.P. F5, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALPN Stock Option (Right to buy) Options Exercise $0 -8.61K -16.81% $0.00 42.6K Dec 12, 2023 Common Stock 8.61K $0.45 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 30, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $17.00 to $17.25. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $17.00 to $17.75. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $17.00 to $17.56. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 Alpine BioVentures GP, LLC is the general partner of Alpine ImmunoSciences, L.P. Dr. Gold is a Managing Partner of Alpine BioVentures GP, LLC. Dr. Gold is also a limited partner of Alpine ImmunoSciences, L.P. By virtue of such relationships, Dr. Gold may be deemed to have voting and investment power with respect to the shares held by Alpine ImmunoSciences, L.P. and as a result may be deemed to have beneficial ownership of such shares.
F6 The Reporting Person disclaims beneficial ownership of the shares of common stock reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F7 100% of the shares underlying the option were fully vested as of January 16, 2019.